Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

UVaDOC. Repositorio Documental de la Universidad de Valladolid
Publicación Artículo científico (JournalArticle)

The Incorporation of etanercept into a porous tri-layer scaffold for restoring and repairing cartilage tissue

  • Campos, Yaima
  • Fuentes, Gastón
  • Almirall, Amisel
  • Que, Ivo
  • Schomann, Timo
  • Chung, Chih Kit
  • Jorquera Cordero, Carla
  • Quintanilla Sierra, Luis
  • Rodríguez Cabello, José Carlos
  • Chan, Alan
  • Cruz, Luis
Producción Científica, Cartilage diseases currently affect a high percentage of the world’s population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capable of dosing these drugs over time in a specific area. The objective of this study was to incorporate etanercept (ETA) into porous three-layer scaffolds to decrease the inflammatory process in this soft tissue. ETA is a blocker of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). For this reason, the scaffold was built based on natural polymers, including chitosan and type I collagen. The scaffold was grafted next to subchondral bone using hydroxyapatite as filler. One of the biomaterials obtained was also crosslinked to compare its mechanical properties with the non-treated one. Both samples’ physicochemical properties were studied with SEM, microCT and photoacoustic imaging, and their rheological properties were also compared. The cell viability and proliferation of the human chondrocyte C28/I2 cell line were studied in vitro. An in vitro and in vivo controlled release study was evaluated in both specimens. The ETA anti-inflammatory effect was also studied by in vitro TNF-α and IL-6 production. The crosslinked and non-treated scaffolds had rheological properties suitable for this application. They were non-cytotoxic and favoured the in vitro growth of chondrocytes. The in vitro and in vivo ETA release showed desirable results for a drug delivery system. The TNF-α and IL-6 production assay showed that this drug was effective as an anti-inflammatory agent. In an in vivo OA mice model, safranin-O and fast green staining was carried out. The OA cartilage tissue improved when the scaffold with ETA was grafted in the damaged area. These results demonstrate that this type of biomaterial has high potential for clinical applications in tissue engineering and as a controlled drug delivery system in OA articular cartilage., European Union through the Erasmus PLUS doctoral fellowship (project 2015-1-NL01-KA 107-008639), VIDI personal grant (project 723.012.110)
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies

  • Scott, Jamie I.
  • Mendive Tapia, Lorena
  • Gordon, Doireann
  • Barth, Nicole D.
  • Thompson, Emily J.
  • Cheng, Zhiming
  • Taggart, David
  • Kitamura, Takanori
  • Bravo-Blas, Alberto
  • Roberts, Edward W.
  • Juárez Jiménez, Jordi
  • Michel, Julien
  • Piet, Berber
  • Vries, I. Jolanda de
  • Verdoes, Martijn
  • Dawson, John
  • Carragher, Neil
  • O' Connor, Richard A.
  • Akram, Ahsan R.
  • Frame, Margaret
  • Serrels, Alan
  • Vendrell, Marc
Immunotherapy promotes the attack of cancer cells by the immune system; however, it is difficult to detect early responses before changes in tumor size occur. Here, we report the rational design of a fluorogenic peptide able to detect picomolar concentrations of active granzyme B as a biomarker of immune-mediated anticancer action. Through a series of chemical iterations and molecular dynamics simulations, we synthesize a library of FRET peptides and identify probe H5 with an optimal fit into granzyme B. We demonstrate that probe H5 enables the real-time detection of T cell-mediated anticancer activity in mouse tumors and in tumors from lung cancer patients. Furthermore, we show image-based phenotypic screens, which reveal that the AKT kinase inhibitor AZD5363 shows immune-mediated anticancer activity. The reactivity of probe H5 may enable the monitoring of early responses to anticancer treatments using tissue biopsies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fluorogenic Granzyme A substrates enable real-time imaging of adaptive immune cell activity

  • Cheng, Zhiming
  • Thompson, Emily J.
  • Mendive-Tapia, Lorena
  • Scott, Jamie I.
  • Benson, Sam
  • Kitamura, Takanori
  • Senán Salinas, Ana
  • Samarakoon, Youhani
  • Roberts, Edward W.
  • Arias, Maykel
  • Pardo, Julián
  • Gálvez Buerba, Eva Mª
6 figures., Cytotoxic immune cells, including T lymphocytes (CTLs) and natural killer (NK) cells, are essential components of the host response against tumors. CTLs and NK cells secrete granzyme A (GzmA) upon recognition of cancer cells; however, there are very few tools that can detect physiological levels of active GzmA with high spatiotemporal resolution. Herein, we report the rational design of the near-infrared fluorogenic substrates for human GzmA and mouse GzmA. These activity-based probes display very high catalytic efficiency and selectivity over other granzymes, as shown in tissue lysates from wild-type and GzmA knock-out mice. Furthermore, we demonstrate that the probes can image how adaptive immune cells respond to antigen-driven recognition of cancer cells in real time., A. S. acknowledges a PhD fellowship from the Aragon Government. M. A. A. acknowledges funds from the Ministry of Economy and Competitiveness, Spain (IJC2019- 039192-I). This research was supported by CIBER (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU, FEDER (Group B29_20R), Ministry of Science, Innovation and Universities and Agencia Estatal de Investigación, Spain (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). T. K. acknowledges funding from an MRC Career Development Award (MR/S006982/1) and an MRC Centre Grant (MR/N022556/1). E. W. R. acknowledges a Cancer Research UK grant (A_BICR_1920_Roberts). M. V. acknowledges funds from an ERC Consolidator Grant (DYNAFLUORS, 771443) and an ERC PoC Grant (IBDIMAGE, 957535). This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (859908)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective detection of active extracellular granzyme A by using a novel fluorescent immunoprobe with application to inflammatory diseases

  • Senán Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, María Pilar
  • Ramírez-Labrada, Ariel
  • Paño, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel
  • Gálvez Buerba, Eva Mª
8 figures.-- Supplementary information available., Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases., This research was supported by CIBER─Consorcio Centro de Investigación Biomédica en Red─CIBERINFEC (CB21-13-0087), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea─NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R and LMP139_21), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00, SAF2017-83120-C2-1-R). A.S.-S. was supported by a PhD fellowship from the Aragon Government. M.A. acknowledges funds from the Ministry of Economy and Competitiveness, Spain (FJCI-2017-31629, IJC2019-039192-I). M.V. acknowledges funds from an ERC Consolidator Grant (DYNAFLUORS, 771443), and this project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (859908)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Fluorogenic Granzyme A Substrates Enable Real-Time Imaging of Adaptive Immune Cell Activity

  • Cheng, Zhiming
  • Thompson, Emily J
  • Mendive-Tapia, Lorena
  • Scott, Jamie I
  • Benson, Sam
  • Kitamura, Takanori
  • Senan-Salinas, Ana
  • Samarakoon, Youhani
  • Roberts, Edward W
  • Arias, Maykel A
  • Pardo, Julian
  • Galvez, Eva M
  • Vendrell, Marc
Cytotoxic immune cells, including T lymphocytes (CTLs) and natural killer (NK) cells, are essential components of the host response against tumors. CTLs and NK cells secrete granzyme A (GzmA) upon recognition of cancer cells; however, there are very few tools that can detect physiological levels of active GzmA with high spatiotemporal resolution. Herein, we report the rational design of the near‐infrared fluorogenic substrates for human GzmA and mouse GzmA. These activity‐based probes display very high catalytic efficiency and selectivity over other granzymes, as shown in tissue lysates from wild‐type and GzmA knock‐out mice. Furthermore, we demonstrate that the probes can image how adaptive immune cells respond to antigen‐driven recognition of cancer cells in real time.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Selective Detection of Active Extracellular Granzyme A by Using a Novel Fluorescent Immunoprobe with Application to Inflammatory Diseases

  • Senan-Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón-Tituaña, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, Maria Pilar
  • Ramírez-Labrada, Ariel
  • Paño-Pardo, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel A.
  • Galvez, Eva M.
Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies

  • Scott, Jamie I.
  • Mendive Tapia, Lorena
  • Gordon, Doireann
  • Barth, Nicole D.
  • Thompson, Emily J.
  • Cheng, Zhiming
  • Taggart, David
  • Kitamura, Takanori
  • Bravo-Blas, Alberto
  • Roberts, Edward W.
  • Juárez Jiménez, Jordi
  • Michel, Julien
  • Piet, Berber
  • Vries, I. Jolanda de
  • Verdoes, Martijn
  • Dawson, John
  • Carragher, Neil
  • O' Connor, Richard A.
  • Akram, Ahsan R.
  • Frame, Margaret
  • Serrels, Alan
  • Vendrell, Marc
Immunotherapy promotes the attack of cancer cells by the immune system; however, it is difficult to detect early responses before changes in tumor size occur. Here, we report the rational design of a fluorogenic peptide able to detect picomolar concentrations of active granzyme B as a biomarker of immune-mediated anticancer action. Through a series of chemical iterations and molecular dynamics simulations, we synthesize a library of FRET peptides and identify probe H5 with an optimal fit into granzyme B. We demonstrate that probe H5 enables the real-time detection of T cell-mediated anticancer activity in mouse tumors and in tumors from lung cancer patients. Furthermore, we show image-based phenotypic screens, which reveal that the AKT kinase inhibitor AZD5363 shows immune-mediated anticancer activity. The reactivity of probe H5 may enable the monitoring of early responses to anticancer treatments using tissue biopsies.